Alpha Cognition Receives Army Medical Research Grant for Study on Mild Traumatic Brain Injury (mTBI) from Blast Induced Functional Deficit and Brain Pathology

Author's Avatar
Jun 07, 2023

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the that it has been awarded a $750,000 grant from the Army Medical Research and Material Command (AMRMC) for a pre-clinical study on the use of ALPHA-1062 Intranasal (IN) to reduce blast mTBI induced functional deficit and brain abnormalities.